BMG Pharma S.r.l. and Julphar - Gulf Pharmaceutical Industries Announce the Signature of a License and Supply Agreement for the Commercialization of BMG Pharma Women's Health Products Ginoxil® in MEA Territories

Jul 25, 2013, 03:00 ET from BMG Pharma S.r.l.

MILAN and RAS AL KHAIMHA, UAE, July 25, 2013 /PRNewswire/ --

BMG Pharma S.r.l and Julphar - Gulf Pharmaceutical Industries are pleased to announce a partnership for the commercialization of proprietary technology products in women's health under the BMG Ginoxil brand in the Middle East and Africa. Under the terms of the License and Supply Agreement, Julphar will exclusively register and commercialize BMG's highly innovative gynecological products.

The Agreement will enable Julphar to rapidly introduce this innovative women's health portfolio in a fast growing and largely self-payment driven market. These products have been developed to address major unmet needs for patients and physicians in the evolving MEA market. Julphar expects to launch this family of products directly from early 2014 onwards.

"We believe this partnership with Julphar, a leading company in the MEA countries with whom we share vision and values, is the key to growing sales of BMG's women's health products. BMG's proven innovation capabilities complements Julphar's deep understanding of the evolving needs in MEA's healthcare market," said Marco Mastrodonato, President and CEO of BMG Pharma S.r.l. "This long-term partnership is a major milestone for BMG as it opens us the door to one of the most exciting healthcare markets in the world."

"Julphar recognizes and acknowledges market demands within our region for increasing accessibility of specialized women's products. It is an honor to partner with BMG on this mission to fulfill a clearly identified market need and provide high-quality products. Women's health is a sizable market segment which has been somewhat under-served in our region; we look forward to continuing to expand our portfolio and better serving patients' needs." 

About BMG Pharma S.r.l

BMG Pharma S.r.l. is an Italian Specialty Pharmaceutical Company leveraging its proprietary technology to develop products that address unmet needs of patients. The Company is currently focused on cancer supportive care, dermatology, gynecology, ENT and oral health. BMG Pharma S.r.l. is dedicated to helping patients, pharmacists and physicians by providing valuable and innovative products to the market.

For press releases and other company information, visit:

About Julphar

Established in 1980, Julphar is a regional leader in the production and distribution of high quality, affordable pharmaceutical products.

The Julphar manufacturing network consists of twelve world-class production facilities (with further expansion planned) and a reliable logistics network which spans five continents.

Their diverse product portfolio contains over 800 products and targets major therapeutic segments including endocrinology, anti-infective, cardiovascular and gastroenterology, over-the-counter, nephrology, dermatology, respiratory, metabolic and burn and wound management.

In 2012, Julphar became the only company in the Middle East to produce the raw material needed to make insulin, through the launch of a division entirely dedicated to Diabetes.

Loredana Galli

SOURCE BMG Pharma S.r.l.